Summary
University of Cambridge (UC) is an educational and research institute that offers undergraduate and graduate studies. The institute offers undergraduate courses in areas of architecture, chemical engineering, classics, computer science. It provides courses such as economics, education, engineering, English, land economy, law, linguistics, natural sciences, human, social, and political sciences, veterinary medicine, theology and religious studies. UC’s course area includes philosophy, psychological and behavioral sciences, mathematics, medicine and management studies, among others. The institute provides undergraduate program through its affiliated colleges. It also conducts research programs on infectious diseases, cancer, biological and biomedical sciences. UC is headquartered in Cambridge, the UK.
University of Cambridge - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
University of Cambridge, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
University of Cambridge, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
University of Cambridge, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
University of Cambridge, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
University of Cambridge, Medical Devices Deals, 2011 to YTD 2017 11
University of Cambridge, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
University of Cambridge, Pharmaceuticals & Healthcare, Deal Details 16
Venture Financing 16
Z Factor Raises USD9 Million in Series A Venture Financing 16
ApcinteX Raises USD17.6 Million in Series A Financing 17
Carrick Therapeutics Raises USD95 Million in Venture Financing 18
DefiniGEN Raises USD2.2 Million in Venture Financing 19
Cambridge Epigenetix Raises USD21 Million in Series B Financing 20
Morphogen-IX Raises USD2.13 Million in Seed Financing 21
Quethera Raises Funds in Seed Financing Round 22
Fluidic Analytics Raises USD7 Million in Series B Financing 23
PhoreMost Raises USD3.8 Million in Seed Financing 24
Fluidic Analytics Raises USD2.4 Million in Series A Venture Financing 25
Cambridge Epigenetix Raises USD5.5 Million in Series A Venture Financing 26
DefiniGEN Raises USD3.8 Million in Series A Financing 27
Horizon Discovery Raises US$10.5 Million In Final Closing Of Series C Financing 28
Sphere Fluidics Raises US$2.5 Million In Venture Financing 30
Partnerships 32
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 32
PhoreMost Enters into Research Agreement with University of Cambridge 33
Genestack Partners with Cancer Molecular Diagnostic Laboratory 34
OncoTherics Enters into Agreement with University of Cambridge 35
AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 36
MedImmune Enters Into Research Agreement With Cambridge University 38
GlaxoSmithKline Enters Into Co-Development Agreement With University of Cambridge 39
University of Cambridge Enters Into Joint Venture Agreement With Elan 40
Phylogica Enters Into Joint Venture Agreement With University Of Cambridge 41
AstraZeneca Enters Into Joint Venture With Sanofi, University Of Cambridge, EPFL, And Universities Of Pavia And Uppsala 42
Licensing Agreements 44
Qkine Enters into Licensing Agreement with Cambridge Enterprise 44
Cantabio Pharma Enters into Licensing Agreement with University of Cambridge 45
Storm Therapeutics Receives Intellectual Property Rights from University of Cambridge and Cancer Research UK 47
XO1 Enters into Licensing Agreement with Cambridge Enterprise 48
DefiniGEN Enters into Licensing Agreement with University of Cambridge 49
Sphere Fluidics Enters Into Licensing Agreement with Cambridge University for Picodroplets 50
Equity Offering 51
Qkine Spin Out from University of Cambridge 51
Morphogen-IX Spin Out from University of Cambridge 52
Z Factor Spin Out from University of Cambridge 53
Fluidic Analytics Spin Out from University of Cambridge 54
Acquisition 55
Nihon Trim To Acquire 50.1% Stake In StemCell Institute For US$5.3 Million 55
SuperGen Completes Acquisition Of Astex Therapeutics 56
University of Cambridge - Key Competitors 59
University of Cambridge - Key Employees 60
University of Cambridge - Locations And Subsidiaries 61
Head Office 61
Other Locations & Subsidiaries 61
Joint Venture 62
Recent Developments 63
Strategy And Business Planning 63
Oct 03, 2016: Cambridge Enterprise joins largest-ever early stage investment in a UK university spin-out 63
Government and Public Interest 65
Jul 03, 2017: Artificial bile ducts grown in lab and transplanted into mice could help treat liver disease in children 65
Jun 20, 2017: Age-specific overall risk of breast, ovarian cancer among women with BRCA1/2 genetic mutations 66
Mar 27, 2017: Major genetic study identifies 12 new genetic variants for ovarian cancer 67
Mar 23, 2017: New stem cell method produces millions of human brain and muscle cells in days 68
Nov 23, 2016: New imaging technique measures toxicity of proteins associated with Alzheimer’s and Parkinson’s diseases 69
Nov 16, 2016: Two Female Scientists in the US and UK Granted $400,000 for Promising Lung Cancer Research 70
Oct 18, 2016: Anti-inflammatory drugs could help treat symptoms of depression, study suggests 71
Sep 19, 2016: Parkinson's disease protein plays vital 'marshalling' role in healthy brains 72
Sep 12, 2016: Quadruple helix form of DNA may aid in the development of targeted cancer therapies 73
Jul 18, 2016: Scientists discover how proteins in the brain build-up rapidly in Alzheimer's 74
Jun 01, 2016: Genetic approach could help identify side-effects at early stages of drug development 75
May 25, 2016: More genetic risk factors for endometrial cancer uncovered 76
Mar 04, 2016: Scientists develop very early stage human embryonic stem cell lines for first time 77
Feb 12, 2016: Researchers identify 'neurostatin' that may reduce the risk of Alzheimer's disease 78
Product News 80
Nov 29, 2016: Enhanced CRISPR lets scientists explore all steps of health and disease in every cell type 80
Aug 23, 2016: IXICO and Cambridge Cluster Study to Detect Early Signs of Alzheimer's Disease 81
Jul 28, 2017: Ground-Breaking Alzheimer’s Trial Available To Patients Across Northern Ireland 82
Jul 06, 2017: Cantabio Announces Publication of Study Results by University of Cambridge researchers in ACS Chemical Neuroscience 83
Jan 16, 2017: Cambridge scientists make revolutionary discovery for Parkinson's Disease 84
Appendix 86
Methodology 86
About GlobalData 86
Contact Us 86
Disclaimer 86
List of Tables
University of Cambridge, Pharmaceuticals & Healthcare, Key Facts 2
University of Cambridge, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
University of Cambridge, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
University of Cambridge, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
University of Cambridge, Deals By Therapy Area, 2011 to YTD 2017 10
University of Cambridge, Medical Devices Deals, 2011 to YTD 2017 11
University of Cambridge, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Z Factor Raises USD9 Million in Series A Venture Financing 16
ApcinteX Raises USD17.6 Million in Series A Financing 17
Carrick Therapeutics Raises USD95 Million in Venture Financing 18
DefiniGEN Raises USD2.2 Million in Venture Financing 19
Cambridge Epigenetix Raises USD21 Million in Series B Financing 20
Morphogen-IX Raises USD2.13 Million in Seed Financing 21
Quethera Raises Funds in Seed Financing Round 22
Fluidic Analytics Raises USD7 Million in Series B Financing 23
PhoreMost Raises USD3.8 Million in Seed Financing 24
Fluidic Analytics Raises USD2.4 Million in Series A Venture Financing 25
Cambridge Epigenetix Raises USD5.5 Million in Series A Venture Financing 26
DefiniGEN Raises USD3.8 Million in Series A Financing 27
Horizon Discovery Raises US$10.5 Million In Final Closing Of Series C Financing 28
Sphere Fluidics Raises US$2.5 Million In Venture Financing 30
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 32
PhoreMost Enters into Research Agreement with University of Cambridge 33
Genestack Partners with Cancer Molecular Diagnostic Laboratory 34
OncoTherics Enters into Agreement with University of Cambridge 35
AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 36
MedImmune Enters Into Research Agreement With Cambridge University 38
GlaxoSmithKline Enters Into Co-Development Agreement With University of Cambridge 39
University of Cambridge Enters Into Joint Venture Agreement With Elan 40
Phylogica Enters Into Joint Venture Agreement With University Of Cambridge 41
AstraZeneca Enters Into Joint Venture With Sanofi, University Of Cambridge, EPFL, And Universities Of Pavia And Uppsala 42
Qkine Enters into Licensing Agreement with Cambridge Enterprise 44
Cantabio Pharma Enters into Licensing Agreement with University of Cambridge 45
Storm Therapeutics Receives Intellectual Property Rights from University of Cambridge and Cancer Research UK 47
XO1 Enters into Licensing Agreement with Cambridge Enterprise 48
DefiniGEN Enters into Licensing Agreement with University of Cambridge 49
Sphere Fluidics Enters Into Licensing Agreement with Cambridge University for Picodroplets 50
Qkine Spin Out from University of Cambridge 51
Morphogen-IX Spin Out from University of Cambridge 52
Z Factor Spin Out from University of Cambridge 53
Fluidic Analytics Spin Out from University of Cambridge 54
Nihon Trim To Acquire 50.1% Stake In StemCell Institute For US$5.3 Million 55
SuperGen Completes Acquisition Of Astex Therapeutics 56
University of Cambridge, Key Competitors 59
University of Cambridge, Key Employees 60
University of Cambridge, Other Locations 61
University of Cambridge, Subsidiaries 61
University of Cambridge, Joint Venture 62
